NCT00238797 2011-01-21A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma MultiformeAstraZenecaPhase 2 Completed36 enrolled